There are currently 138 clinical trials in Tyler, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including Texas Oncology - Tyler, Tyler Cancer Center, Tyler Research Institute, LLC and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease
NCT03464097
Recruiting
This is a study to demonstrate the effect of oral ozanimod as maintenance therapy in participants with moderately to severely active Crohn's Disease.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/14/2024
Locations: Local Institution - 073, Tyler, Texas
Conditions: Crohn Disease
Register for Updates
A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease
NCT05668013
Recruiting
The primary objective of the study is to evaluate the efficacy of 2 different maintenance dose regimens of TEV-48574 subcutaneous (sc) administered every 4 weeks (Q4W) in adult participants with inflammatory bowel disease (IBD). Secondary objectives of the study are to: evaluate the efficacy of 2 different maintenance dose regimens of TEV-48574 sc administered Q4W in adult participants with IBD evaluate the safety and tolerability of 2 different maintenance dose regimens of TEV-48574 sc admini... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/14/2024
Locations: Teva Investigational Site 15361, Tyler, Texas
Conditions: Crohn Disease, Colitis, Ulcerative
Register for Updates
Product Surveillance Registry
NCT01524276
Recruiting
The purpose of the Registry is to provide continuing evaluation and periodic reporting of safety and effectiveness of Medtronic market-released products. The Registry data is intended to benefit and support interests of patients, hospitals, clinicians, regulatory bodies, payers, and industry by streamlining the clinical surveillance process and facilitating leading edge performance assessment via the least burdensome approach.
Gender:
All
Ages:
All
Trial Updated:
06/13/2024
Locations: Not set, Tyler, Texas
Conditions: Cardiac Rhythm Disorders, Urological Disorders, Neurological Disorders, Cardiovascular Disorders, Digestive Disorders, Intracranial Aneurysm, Mechanical Circulatory Support, Respiratory Therapy, Aortic, Peripheral Vascular and Venous Disorders, Minimally Invasive Surgical Procedures, Diagnostic Techniques and Procedures, Surgical Procedures, Operative, Renal Insufficiency, Neurovascular, Coronary Artery Disease, Ear, Nose and Throat Disorder
Register for Updates
Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer
NCT05766748
Recruiting
This is an open label study to determine the safety and preliminary evidence of a therapeutic effect of azeliragon in patients refractory to prior treatment of metastatic pancreatic cancer.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
06/13/2024
Locations: Texas Oncology - Northeast Texas, Tyler, Texas
Conditions: Metastatic Pancreatic Cancer
Register for Updates
THUNDER: Acute Ischemic Stroke Study With the Penumbra System® Including Thunderbolt™ Aspiration Tubing
NCT05437055
Recruiting
The objective of this study is to demonstrate the safety and efficacy of the Penumbra System including Thunderbolt Aspiration Tubing (Thunderbolt) in a population presenting with acute ischemic stroke (AIS) secondary to intracranial large vessel occlusion (LVO) who are eligible for mechanical thrombectomy.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
06/12/2024
Locations: Christus Trinity Medical Center, Tyler, Texas
Conditions: Acute Ischemic Stroke, Large Vessel Occlusion
Register for Updates
Study of Tazemetostat Versus Placebo When Given in Combination With Lenalidomide and Rituximab in Participants With Relapsed/Refractory Follicular Lymphoma
NCT04224493
Recruiting
The participants of this study would have relapsed/refractory follicular lymphoma. Follicular lymphoma is a type of blood cancer. It is referred to as 'relapsed' when the disease has come back after a period of improvement after that follows a treatment regimen and 'refractory' when treatment no longer works. Stage 1 of this trial will study the safety and the level that adverse effects of each of the study drug combinations can be tolerated (known as tolerability). It is also designed to esta... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/12/2024
Locations: UT Health East Texas HOPE Cancer Center - Tyler, Tyler, Texas +1 locations
Conditions: Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
Register for Updates
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
NCT00781612
Recruiting
This is a global, multicenter, open-label safety extension study. Participants receiving single-agent trastuzumab emtansine or trastuzumab emtansine administered in combination with other anti-cancer therapies in a Genentech / Roche-sponsored parent study who are active and receiving benefit at the closure of parent study are eligible for continued treatment in this study.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/12/2024
Locations: USO - Tyler Cancer Ctr, Tyler, Texas
Conditions: Neoplasm Metastasis
Register for Updates
A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab))
NCT05731128
Recruiting
The protocol of this Phase 2 clinical trial consists of a double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of dupilumab in participants with moderately to severely active Ulcerative Colitis (UC) with an eosinophilic phenotype. Screening period: 2 to up to 4 weeks Treatment period: 52-week investigational medicinal product (IMP) intervention (dupilumab or matching placebo) from Week 0 to Week 52 Open-label arm (optional): administration of... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/12/2024
Locations: Tyler Research Institute Site Number : 8400031, Tyler, Texas
Conditions: Colitis Ulcerative
Register for Updates
Clinical Study of Ivonescimab for First-line Treatment of Metastatic Squamous NSCLC Patients
NCT05899608
Recruiting
This is a Phase 3 Randomized, Controlled, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer. The primary endpoint is overall survival and key secondary endpoints include progression free survival. response and safety.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/11/2024
Locations: Summit Therapeutics Research Center, Tyler, Texas
Conditions: Non-Small Cell Lung Cancer
Register for Updates
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
NCT05952557
Recruiting
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy). The planned duration of treatment in either arm within the study will be 7 years.
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
06/11/2024
Locations: Research Site, Tyler, Texas
Conditions: Breast Cancer, Early Breast Cancer
Register for Updates
Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine
NCT05846230
Recruiting
This study is open to adults aged 18 years and older with bronchiectasis. People can join the study if they were previously enrolled in another study with BI 1291583 (1397-0012: Airleafᵀᴹ). The purpose of this study is to find out whether a medicine called BI 1291583 helps people with bronchiectasis, an inflammatory lung condition. The investigators also want to know how well people with this condition can tolerate BI 1291583 in the long term. Participants take a low, medium, or high dose of BI... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: University of Texas Health Science Center at Tyler, Tyler, Texas
Conditions: Bronchiectasis
Register for Updates
Assessment of Combined CCM and ICD Device in HFrEF
NCT05855135
Recruiting
The goal of this clinical trial is to demonstrate that the OPTIMIZER® Integra CCM-D System (the "CCM-D System") can safely and effective convert induced ventricular fibrillation (VF) and spontaneous ventricular tachycardia and/or ventricular fibrillation (VT/VF) episodes in subjects with Stage C or D heart failure who remain symptomatic despite being on guideline-directed medical therapy (GDMT), are not indicated for cardiac resynchronization therapy (CRT), and have heart failure with reduced le... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: Christus Trinity Clinic, Tyler, Texas
Conditions: Heart Failure, Heart Failure With Reduced Ejection Fraction, Implantable Defibrillator User, CCM Therapy, Non-ischemic Cardiomyopathy, Ischemic Cardiomyopathy, Sudden Cardiac Arrest, Arrhythmias, Cardiac, Ventricular Tachycardia, Ventricular Fibrillation
Register for Updates